perampanel Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antagonists of the ionotropic non-NMDA (N-methyl-D-aspartate) glutamate receptors (Namely the AMPA (amino-hydroxymethyl-isoxazole-propionic acid) and/or KA (kainite antagonist) receptors) 4684 380917-97-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • perampanel hydrate
  • perampanel
  • fycompa
  • E2007
  • E-2007
a non-competitive AMPA glutamate receptor antagonist indicated as adjunctive therapy for the treatment of seizures
  • Molecular weight: 349.39
  • Formula: C23H15N3O
  • CLOGP: 4.17
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 56.99
  • ALOGS: -4.80
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
8 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 1.36 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 183 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 22, 2012 FDA EISAI INC
Jan. 23, 2020 PMDA Eisai Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aggression 372.42 37.79 111 2908 22633 46660410
Seizure 215.68 37.79 120 2899 122934 46560109
Irritability 197.16 37.79 73 2946 28873 46654170
Status epilepticus 193.21 37.79 60 2959 13919 46669124
Multiple-drug resistance 110.78 37.79 27 2992 2538 46680505
Suicidal ideation 106.61 37.79 58 2961 56324 46626719
Epilepsy 105.48 37.79 44 2975 23694 46659349
Mood altered 74.64 37.79 29 2990 12978 46670065
Suicide attempt 67.96 37.79 43 2976 54993 46628050
Psychotic disorder 65.27 37.79 31 2988 22590 46660453
Dizziness 63.87 37.79 93 2926 340321 46342722
Drug resistance 60.09 37.79 27 2992 17341 46665702
Somnolence 50.27 37.79 56 2963 156465 46526578
Drug ineffective 48.81 37.79 123 2896 677715 46005328
Drug interaction 44.65 37.79 60 2959 203034 46480009
Agitation 43.99 37.79 33 2986 55382 46627661
Intentional overdose 41.45 37.79 34 2985 64910 46618133
Generalised tonic-clonic seizure 38.02 37.79 23 2996 27099 46655944

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aggression 430.42 40.86 152 2656 36755 29912915
Seizure 220.35 40.86 128 2680 98347 29851323
Suicide attempt 154.32 40.86 73 2735 36624 29913046
Status epilepticus 153.03 40.86 52 2756 11020 29938650
Irritability 119.21 40.86 53 2755 22997 29926673
Anger 107.21 40.86 40 2768 11080 29938590
Epilepsy 84.23 40.86 40 2768 20129 29929541
Intentional overdose 79.41 40.86 49 2759 41432 29908238
Homicidal ideation 78.57 40.86 22 2786 2441 29947229
Suicidal ideation 69.96 40.86 43 2765 36071 29913599
Somnolence 64.81 40.86 61 2747 96702 29852968
Pneumonia aspiration 58.33 40.86 39 2769 37741 29911929
Agitation 54.26 40.86 43 2765 54030 29895640
Multiple-drug resistance 53.39 40.86 17 2791 2924 29946746
Abnormal behaviour 48.28 40.86 30 2778 25593 29924077
Psychotic disorder 47.79 40.86 28 2780 21487 29928183
Sudden unexplained death in epilepsy 44.74 40.86 10 2798 440 29949230

Pharmacologic Action:

SourceCodeDescription
ATC N03AX22 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Other antiepileptics
FDA MoA N0000020016 AMPA Receptor Antagonists
FDA EPC N0000186106 Noncompetitive AMPA Glutamate Receptor Antagonist
CHEBI has role CHEBI:35623 antiepileptic
CHEBI has role CHEBI:71014 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Partial seizure indication 29753000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.89 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glutamate receptor ionotropic AMPA Ion channel ANTAGONIST IC50 6.61 CHEMBL CHEMBL

External reference:

IDSource
D08964 KEGG_DRUG
4032964 VUID
N0000189940 NUI
4032964 VANDF
C4721962 UMLSCUI
CHEBI:71013 CHEBI
6ZP PDB_CHEM_ID
CHEMBL1214124 ChEMBL_ID
DB08883 DRUGBANK_ID
C551441 MESH_SUPPLEMENTAL_RECORD_UI
9924495 PUBCHEM_CID
7050 IUPHAR_LIGAND_ID
8834 INN_ID
H821664NPK UNII
1356552 RXNORM
192918 MMSL
28817 MMSL
d07904 MMSL
014644 NDDF
703127006 SNOMEDCT_US
703728005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-272 TABLET 2 mg ORAL NDA 35 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-274 TABLET 4 mg ORAL NDA 35 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-276 TABLET 6 mg ORAL NDA 35 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-278 TABLET 8 mg ORAL NDA 35 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-280 TABLET 10 mg ORAL NDA 35 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-282 TABLET 12 mg ORAL NDA 35 sections
Fycompa HUMAN PRESCRIPTION DRUG LABEL 1 62856-290 SUSPENSION 0.50 mg ORAL NDA 35 sections